Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis

ConclusionWe found that some patients showed no evidence of disease after the interruption of trastuzumab therapy. Discontinuation of maintenance trastuzumab in this patient population after a limited time should be explored cautiously while awaiting a global collaborative effort for a randomized trial.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research